
Opinion|Videos|October 2, 2024
Navigating Toxicity: Comparing Third-Line mCRC Therapies
Medical experts compare the toxicity profiles of FTD/TPI plus bevacizumab, regorafenib, and fruquintinib, and discuss practical strategies for managing treatment-related toxicities with these third-line therapies.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do the toxicity profiles differ with FTD/TPI plus bevacizumab, as compared with regorafenib or fruquintinib, and how might these different toxicity profiles be leveraged when making treatment selections?
- What are some key, practical strategies you use to manage treatment-related toxicities with these third-line therapies?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Single-Tablet Bictegravir/Lenacapavir Effective After Treatment Switch
2
Newly Identified RTEL1 Variant Could Broaden Genetic Landscape of Familial PF
3
Chemoradiotherapy Improved Survival in Older Patients With Stage 2 NSCLC
4
Review Highlights IGHV Testing Complexities in CLL
5















































